about
Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antiviralsHepatitis C virus infection and prisoners: Epidemiology, outcome and treatmentClinical impact of occult hepatitis B virus infection in immunosuppressed patientsCannabinoid receptor 2-63 QQ variant is associated with persistently normal aminotransferase serum levels in chronic hepatitis CHepatic flares in chronic hepatitis C: spontaneous exacerbation vs hepatotropic viruses superinfection.Epidemiology of acute and chronic hepatitis B and delta over the last 5 decades in ItalyInsulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progressionPrevalence of latent tuberculosis infection and associated risk factors among 3,374 healthcare students in Italy.Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus.Efficacy of Pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis.Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progressionPeg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictorsThe long-term immunogenicity of recombinant hepatitis B virus (HBV) vaccine: contribution of universal HBV vaccination in ItalyImpact of comorbidities on the severity of chronic hepatitis B at presentationRituximab-based treatment, HCV replication, and hepatic flares.Virus Variability and Its Impact on HIV and Hepatitis Therapy.A Simple Noninvasive Score Based on Routine Parameters can Predict Liver Cirrhosis in Patients With Chronic Hepatitis C.Clinical applications of antibody avidity and immunoglobulin M testing in acute HCV infection.Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A.Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment.Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.Recommendations for the management of acute hepatitis B: position paper of the Italian Society for the Study of Infectious and Tropical Diseases (SIMIT).Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection.GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection.Different Impact Of Antiretroviral Drugs On Bone Differentiation In An In Vitro Model.Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013.Lipodystrophy and serum lipid abnormalities in HIV-positive sub-Saharan population on ART.Age and gender distribution of hepatitis C virus genotypes in the metropolitan area of Naples.The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases.Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B.The impact of the CB2-63 polymorphism on the histological presentation of chronic hepatitis B.TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism.Distribution pattern of hepatitis C virus genotypes and correlation with viral load and risk factors in chronic positive patients.The reactivation of occult HBV infection emerging with the case of acute hepatitis B in the wife of a subject treated with rituximab-based chemotherapy.Molecular epidemiology of hepatitis B virus genotypes circulating in acute hepatitis B patients in the Campania region.Clinical and virological characteristics associated with severe acute hepatitis B.Functional interplay between hepatitis B virus X protein and human miR-125a in HBV infection.Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients.Role of interleukin 28-B in the spontaneous and treatment-related clearance of HCV infection in patients with chronic HBV/HCV dual infection.HBV transmission from an occult carrier with five mutations in the major hydrophilic region of HBsAg to an immunosuppressed plasma recipient.
P50
Q26782033-5E56EB5E-82A2-46CC-A32B-4D8D7E66F9EFQ26785981-4E744B8D-5D2B-4E49-8C0C-3366526C6852Q27006996-BE70114E-D366-4F54-ACAE-7C79F55862D0Q28539814-4A80F42D-A636-4B20-AEF8-6DBD52868733Q33735206-168ECCE9-27E9-4EAB-AA78-C144D7892C93Q33801300-62CBF70A-B935-4915-A575-D2AB41D71F95Q34263370-E58BA87B-342C-4DDF-BFF7-C3B7286D36ABQ34309664-A8CE8265-C41B-4E5D-96A5-BA2A114D1DA9Q34420891-625A9344-85E1-496D-BC0A-E9BD75B5F038Q34514292-762D82D4-4633-4F1B-B37C-A7DB94D1D0F6Q34811974-2C047D3B-C7C4-4955-BD1A-00F6DF5FADC5Q35146790-8BE9B7AC-45AE-4EA7-8D2D-2137D9882F48Q35224155-FF909B5B-0D60-49F9-8E46-9BCEC3D79D52Q35886670-8D1349FF-9C43-4DB3-9E19-27C4835D796CQ36167378-929F619A-F195-422C-83AB-207751B2C2A8Q36522440-5BA1F12C-2450-41D2-85F5-DF880D0222B5Q37090659-6A267FC2-0E6B-4ACB-945F-9BAD37B308ADQ38074390-C38CC7BC-FCEF-44D3-99F4-50EE167A914FQ38174092-05BA4335-BC96-44EE-A56A-E77AA56D572DQ38195262-0C3C245D-24A3-44E4-AAAE-F9E63817DF30Q38207725-145BC3A2-DBAC-4604-985B-D84828920567Q38226627-C5D00766-0900-4870-8D85-ED473CD0FAA0Q38233860-BE3D7629-4F6A-4B72-AAB4-50404CA8556AQ38237281-ACDC36F1-6FD9-4BFA-BCB8-3C014C5C2CB7Q38895284-1552BC16-7FEF-4223-8B1C-7933B695136CQ38952987-2D5D92B4-E905-4946-91E7-7C78DF4B9A88Q39004446-4BA33660-AC3A-448E-8F8C-D4C8C0268BA9Q40105729-9AA1E627-23BC-41A9-A06D-B3595BAB1805Q40445497-024246E6-9E82-415E-8151-396638137785Q41221366-328F0E67-36FE-49BF-873B-C1125CE03612Q41443935-B4F3EFD8-889C-48F6-8434-372AF4E2733AQ41549262-91C2F7FA-A036-454E-A937-4F721D710C89Q42196360-39098D05-6ACE-4DE8-B1C9-22C5E1DCD2F9Q42201054-F70BB602-79EB-4741-8F6C-C9043C0CB0AAQ42209108-AE10B6A8-C800-4386-8E6A-5B296E2B7FF8Q42210385-15155595-5568-4D0F-99DF-3801F4323D11Q42215454-96998F50-1633-4554-9DA4-C13E69E91178Q42222997-03E74F19-290F-439F-8B00-1355A6BFB8D2Q42245958-F273A865-62B2-40CA-A959-963B0D525813Q42255069-D7D78AD7-378D-4161-98F8-ACE12B481626
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Nicola Coppola
@ast
Nicola Coppola
@en
Nicola Coppola
@es
Nicola Coppola
@nl
Nicola Coppola
@sl
type
label
Nicola Coppola
@ast
Nicola Coppola
@en
Nicola Coppola
@es
Nicola Coppola
@nl
Nicola Coppola
@sl
prefLabel
Nicola Coppola
@ast
Nicola Coppola
@en
Nicola Coppola
@es
Nicola Coppola
@nl
Nicola Coppola
@sl
P106
P1153
7003331117
P21
P31
P496
0000-0001-5897-4949